| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Ethyl acrylate-methyl methacrylate copolymer does not target a specific protein or enzyme as a pharmacological agent. Its utility is as a polymer for industrial applications rather than as a drug targeting specific molecular targets. The copolymer is used in coatings, adhesives, and sealants due to its physical properties.
|
|---|---|
| ln Vitro |
The in vitro activity of Ethyl acrylate-methyl methacrylate copolymer is its function as a polymer material with specific physical properties. The copolymer has good adhesion properties, making it suitable for coatings, adhesives, and sealants. It is characterized by clarity and gloss and is resistant to UV light and weathering.
|
| ln Vivo |
No significant in vivo activity has been reported for Ethyl acrylate-methyl methacrylate copolymer as a therapeutic agent. The compound is primarily utilized as an industrial polymer rather than a pharmacologically active compound. It is not intended for therapeutic use in living organisms.
|
| Enzyme Assay |
In vitro assays for Ethyl acrylate-methyl methacrylate copolymer are not typically performed in the context of biological activity. The polymer is used in industrial applications where its physical properties are characterized by techniques such as tensile testing, adhesion testing, and thermal analysis.
|
| Cell Assay |
For in vitro cellular experiments, Ethyl acrylate-methyl methacrylate copolymer is not typically used in cell-based assays. The polymer is primarily used in industrial applications.
|
| Animal Protocol |
In vivo animal experiments with Ethyl acrylate-methyl methacrylate copolymer are not commonly performed, as the compound is primarily used as an industrial polymer rather than a therapeutic candidate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Ethyl acrylate-methyl methacrylate copolymer have not been characterized, as the compound is an industrial polymer rather than a drug candidate. The copolymer has a density of 1.2 g/mL at 25°C and appears as a solid at room temperature.
|
| Toxicity/Toxicokinetics |
Ethyl acrylate-methyl methacrylate copolymer is intended for industrial use only and not for human therapeutic or diagnostic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| References | |
| Additional Infomation |
Ethyl acrylate-methyl methacrylate copolymer (Neutral methacrylate copolymer) (CAS#: 9010-88-2) is a fully polymerized copolymer of methyl methacrylate and ethyl acrylate used in coatings, adhesives, and sealants. It is characterized by good adhesion, clarity, gloss, and UV resistance. The compound has no clinical or therapeutic applications.
|
| Molecular Formula |
(C5H8O2.C5H8O2)X
|
|---|---|
| Exact Mass |
200.105
|
| CAS # |
9010-88-2
|
| Related CAS # |
113547-51-6;121917-49-5;9010-88-2
|
| PubChem CID |
62704
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2 g/mL at 25ºC(lit.)
|
| Boiling Point |
99.5ºC at 760mmHg
|
| Melting Point |
150ºC
|
| Flash Point |
15.6ºC
|
| Index of Refraction |
n20/D 1.49
|
| LogP |
1.471
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
14
|
| Complexity |
170
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XPNLOZNCOBKRNJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/2C5H8O2/c1-4(2)5(6)7-3;1-3-5(6)7-4-2/h1H2,2-3H3;3H,1,4H2,2H3
|
| Chemical Name |
ethyl prop-2-enoate;methyl 2-methylprop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
